Autonomix Medical, Inc. is a development-stage medical device company building a catheter-based platform that combines neural sensing with radiofrequency ablation. Its lead program is designed to target pain associated with pancreatic cancer through a minimally invasive transvascular approach, with the broader goal of treating other nerve-related disorders as the platform matures. The company is still pre-commercial and is focused on proof-of-concept work, clinical development, and regulatory clearance. Autonomix’s business model is centered on disposable catheter sales to hospital catheter labs rather than large capital equipment placements.
4.45
4.45
| % | |
|---|---|
| Catheter-based sensing and ablation system | 0% The core platform combines diagnostic sensing with therapeutic RF ablation to identify and treat neural targets through a transvascular approach. |
| Disposable catheter consumables | 70% Single-use sensing and ablation catheters intended to be sold to hospitals and catheter labs as recurring procedure consumables. |
| Energy delivery and interface components | 20% RF energy source and software-enabled user interface used to power and control the catheter system. |
| Clinical and regulatory development | 10% Research, pre-clinical testing, and regulatory work supporting first indication approval and future label expansion. |
Autonomix’s expected customers are hospitals and hospital catheter labs that perform interventional procedures...
Buy the disposable catheter system and related components to perform interventional procedures with minimal capital equipment needs.
Primary clinical users who need a familiar catheter workflow and limited training to adopt the platform.
Would use the system for pancreatic cancer pain and other visceral pain indications if clinical validation and approvals are achieved.
Potential buyers for expanded indications such as hypertension, chronic pain, CRPS, and cardiology-related nerve targeting.
Autonomix is headquartered in Texas and also has access to a research and development facility in Pennsylvania...
Autonomix’s near-term strategy is to advance its lead catheter-based sensing and ablation platform through clinical...
Clinical validation is required to prove safety and efficacy and to support regulatory clearance and eventual commercialization.
The company states it needs substantial additional capital to fund operations through commercialization and avoid scaling back the business plan.
Patent protection is central to differentiating the platform against much larger electrophysiology competitors.
A broader indication set could increase the addressable market and improve the long-term commercial value of the platform.
Autonomix faces the typical risks of a development-stage medical device company, including clinical failure, regulatory...
The company states it will need additional financing to meet obligations and execute its business plan, and may need to scale back operations if funding is unavailable.
The lead product is still in development, and success depends on clinical trial outcomes and regulatory clearance.
The company must protect its sensing and ablation technology against infringement claims and competitive copying.
Established electrophysiology players have greater resources, commercial infrastructure, and R&D budgets.
Development work relies heavily on contract engineers, manufacturers, and research organizations, which can create execution and quality risk.
The company relies on digital systems and may handle sensitive information, making it vulnerable to breaches and operational disruption.
STXS · Electromedical & Electrotherapeutic Apparatus
Stereotaxis designs and sells robotic magnetic navigation systems used in minimally invasive cardiac and endovascular procedures.
RNXT · Pharmaceutical Preparations
ADVB · Services-Medical Laboratories
AGTX · Biological Products, (No Diagnostic Substances)
Pharmaceutical Preparations
ADGM · Surgical & Medical Instruments & Apparatus
: 11/08/2026